WIRE — US President Donald Trump has imposed a new tariff policy for imported generic medicines, outlining a phased increase in duties aimed at shifting pharmaceutical manufacturing back to the United States. Under the plan, imported generic drugs will continue to enjoy zero tariff for the next two years before facing steep duty hikes beginning in 2028. Announcing the decision on his Truth Social platform, Trump said the policy is intended to encourage pharmaceutical companies to establish manufacturing facilities in the US instead of relying on overseas production. The proposal is the latest step in his broader strategy to strengthen domestic manufacturing and reduce dependence on imported medicines.
"We aggregate wires to encourage regional discovery, sending readers directly back to the original source to explore full coverage."
This is a normalized overview of the breaking feed event. The complete, official release detailing all points, background context, and statements remains hosted by the original publisher.